Characterization of Vitronectin Effect in 3D Ewing Sarcoma Models: A Digital Microscopic Analysis of Two Cell Lines

Overview

Journal Cancers (Basel)

Publisher MDPI

Specialty Oncology

Date 2024 Oct 16

PMID 39409975

Authors

Amparo Lopez-Carrasco

Karina Parra-Haro

Isaac Vieco-Marti

Sofia Granados-Aparici

Juan Diaz-Martin

Carmen Salguero-Aranda

Delia Acevedo-Leon

Enrique de Alava

Samuel Navarro

Rosa Noguera

Affiliations

Soon will be listed here.

Abstract

Ewing sarcoma (ES) is an aggressive bone and soft-tissue pediatric cancer. High vitronectin (VN) expression has been associated with poor prognosis in other cancers, and we aimed to determine the utility of this extracellular matrix glycoprotein as a biomarker of aggressiveness in ES. Silk fibroin plus gelatin-tyramine hydrogels (HGs) were fabricated with and without cross-linked VN and cultivated with A673 and PDX73 ES cell lines for two and three weeks. VN secretion to culture media was assessed using ELISA. Morphometric analysis was applied for phenotypic characterization. VN release to culture media was higher in 3D models than in monolayer cultures, and intracellular, intercellular, and pericluster presence was also observed. A673-HGs showed lower density of clusters but a proportion of larger clusters than PDX73-HGs, which presented low cluster circularity. The cluster density of A673-HGs without added VN was higher than with added VN and slightly lower in the case of PDX73-HGs. Furthermore, a culture time of three weeks provided no benefits in cluster growth compared to two weeks, especially in A673-HGs. These advances in 3D modeling and digital quantification pave the way for future studies in ES and other cancers to deepen understanding about intra- and intercellular heterogeneity and anti-adhesion VN therapies.

References

Lopez-Carrasco A, Vieco-Marti I, Granados-Aparici S, Acevedo-Leon D, Estan-Capell N, Portugal R . Vitronectin Levels in the Plasma of Neuroblastoma Patients and Culture Media of 3D Models: A Prognostic Circulating Biomarker?. Int J Mol Sci. 2024; 25(16). PMC: 11354570. DOI: 10.3390/ijms25168733. View

Noguera R, Nieto O, Tadeo I, Farinas F, Alvaro T . Extracellular matrix, biotensegrity and tumor microenvironment. An update and overview. Histol Histopathol. 2012; 27(6):693-705. DOI: 10.14670/HH-27.693. View

Rae C, Amato F, Braconi C . Patient-Derived Organoids as a Model for Cancer Drug Discovery. Int J Mol Sci. 2021; 22(7). PMC: 8038043. DOI: 10.3390/ijms22073483. View

Schneider G, Suszynska M, Kakar S, Ratajczak M . Vitronectin in the ascites of human ovarian carcinoma acts as a potent chemoattractant for ovarian carcinoma: Implication for metastasis by cancer stem cells. J Cancer Stem Cell Res. 2017; 4. PMC: 5461934. DOI: 10.14343/JCSCR.2016.4e1005. View

Discher D, Janmey P, Wang Y . Tissue cells feel and respond to the stiffness of their substrate. Science. 2005; 310(5751):1139-43. DOI: 10.1126/science.1116995. View

Ozaki T . Diagnosis and treatment of Ewing sarcoma of the bone: a review article. J Orthop Sci. 2015; 20(2):250-63. PMC: 4366541. DOI: 10.1007/s00776-014-0687-z. View

Sanegre S, Lucantoni F, Burgos-Panadero R, de la Cruz-Merino L, Noguera R, Alvaro Naranjo T . Integrating the Tumor Microenvironment into Cancer Therapy. Cancers (Basel). 2020; 12(6). PMC: 7352326. DOI: 10.3390/cancers12061677. View

Shi K, Lan R, Tao X, Wu C, Hong H, Lin J . Vitronectin significantly influences prognosis in osteosarcoma. Int J Clin Exp Pathol. 2015; 8(9):11364-71. PMC: 4637677. View

Tadeo I, Berbegall A, Escudero L, Alvaro T, Noguera R . Biotensegrity of the extracellular matrix: physiology, dynamic mechanical balance, and implications in oncology and mechanotherapy. Front Oncol. 2014; 4:39. PMC: 3940942. DOI: 10.3389/fonc.2014.00039. View

10.

Elgundi Z, Papanicolaou M, Major G, Cox T, Melrose J, Whitelock J . Cancer Metastasis: The Role of the Extracellular Matrix and the Heparan Sulfate Proteoglycan Perlecan. Front Oncol. 2020; 9:1482. PMC: 6978720. DOI: 10.3389/fonc.2019.01482. View

11.

Chen M, Lu C, Sun J, Chen X, Dai J, Cai J . Diagnostic and prognostic value of serum vitronectin levels in human glioma. J Neurol Sci. 2016; 371:54-59. DOI: 10.1016/j.jns.2016.10.022. View

12.

Lamhamedi-Cherradi S, Santoro M, Ramammoorthy V, Menegaz B, Bartholomeusz G, Iles L . 3D tissue-engineered model of Ewing's sarcoma. Adv Drug Deliv Rev. 2014; 79-80:155-71. PMC: 4397982. DOI: 10.1016/j.addr.2014.07.012. View

13.

Bierbaumer L, Katschnig A, Radic-Sarikas B, Kauer M, Petro J, Hogler S . YAP/TAZ inhibition reduces metastatic potential of Ewing sarcoma cells. Oncogenesis. 2021; 10(1):2. PMC: 7794350. DOI: 10.1038/s41389-020-00294-8. View

14.

Thomas D, Rathinavel A, Radhakrishnan P . Altered glycosylation in cancer: A promising target for biomarkers and therapeutics. Biochim Biophys Acta Rev Cancer. 2020; 1875(1):188464. PMC: 7855613. DOI: 10.1016/j.bbcan.2020.188464. View

15.

Goyal U, Ta M . A novel role of vitronectin in promoting survival of mesenchymal stem cells under serum deprivation stress. Stem Cell Res Ther. 2020; 11(1):181. PMC: 7238575. DOI: 10.1186/s13287-020-01682-y. View

16.

Eaton B, Claude L, Indelicato D, Vatner R, Yeh B, Schwarz R . Ewing sarcoma. Pediatr Blood Cancer. 2021; 68 Suppl 2:e28355. DOI: 10.1002/pbc.28355. View

17.

Ciereszko A, Dietrich M, Slowinska M, Nynca J, Ciborowski M, Kisluk J . Identification of protein changes in the blood plasma of lung cancer patients subjected to chemotherapy using a 2D-DIGE approach. PLoS One. 2019; 14(10):e0223840. PMC: 6797170. DOI: 10.1371/journal.pone.0223840. View

18.

Zhu W, Li W, Yang G, Fu C, Jiang G, Hu Q . Vitronectin silencing inhibits hepatocellular carcinoma in vitro and in vivo. Future Oncol. 2014; 11(2):251-8. DOI: 10.2217/fon.14.202. View

19.

Hashimoto K, Nishimura S, Oka N, Akagi M . Outcomes of comprehensive treatment for primary osteosarcoma. SAGE Open Med. 2020; 8:2050312120923177. PMC: 7249600. DOI: 10.1177/2050312120923177. View

20.

Yuan Z, Li Y, Zhang S, Wang X, Dou H, Yu X . Extracellular matrix remodeling in tumor progression and immune escape: from mechanisms to treatments. Mol Cancer. 2023; 22(1):48. PMC: 10007858. DOI: 10.1186/s12943-023-01744-8. View